{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay) subjects,', 'the ORR was 23% (95% CI: 10.42, 40.14), and the CBR was 77% (95% CI: 59.86,', '89.58). A slightly higher ORR (27%) and CBR (87%) were observed in DLL3-high', '( 50% tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay)', 'subjects.', 'In the Phase 2 Study SCRX001-002 (TRINITY) in patients with SCLC recurrent after at', 'least two systemic chemotherapy regimens, rovalpituzumab tesirine dosed at 0.3 mg/kg', 'every 6 weeks for two cycles (with an option for additional two cycles upon progression', 'occurring > 12 weeks after the second dose) resulted in the following:', 'In DLL3 high @ 75% tumor cells staining positive for DLL3 with VENTANA', 'Rabbit IHC (SP347) DLL3 assay) subjects, ORR of 14% per IRC assessment,', 'median OS of 5.7 months and median PFS of 3.8 months', 'In DLL3 high subjects, the clinical benefit rate was 74% with a median duration', 'of clinical benefit of 3.0 months per IRC assessment', 'Additionally, DLL3 positive (> 25% tumor cells staining positive for DLL3 with', 'VENTANA Rabbit IHC (SP347) DLL3 assay) and DLL3 high groups had comparable', 'response rates given highly overlapping populations where approximately 85% of DLL3', 'positive subjects were also DLL3 high', 'In December 2018, enrollment in Study M16-289 TAHOE (\"A Randomized, Open-Label,', 'Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for', 'Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who', 'have First Disease Progression During or Following Front-Line Platinum-Based', 'Chemotherapy\") was discontinued at the recommendation of the Independent Data', 'Monitoring Committee (IDMC) after review of available efficacy data which', 'demonstrated shorter overall survival in the rovalpituzumab tesirine arm compared with', 'the topotecan control arm. At the time enrollment was halted, 444 DLL3 high (> 75%', 'tumor cells staining positive for DLL3 with VENTANA Rabbit IHC (SP347) DLL3', 'assay) subjects had enrolled on the trial. The IDMC recommended that investigators and', '28']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'subjects make individual decisions as to whether or not to continue treatment based on', 'patient level response. The results of the TAHOE study did not adversely impact the', 'safety profile for rovalpituzumab tesirine.', '19', '3.4', 'Differences Statement', 'This is the first randomized, double-blind, multicenter, Phase 3 study comparing', 'rovalpituzumab tesirine versus placebo as maintenance therapy following first-line', 'platinum-based therapy in subjects with extensive-stage SCLC.', '3.5', 'Benefits and Risks', 'Although response rates to first-line platinum-based chemotherapy in ED SCLC are high,', 'SCLC nearly invariably recurs, which may be attributed to the relative resistance of', 'cancer stem cells (CSCs)/TICs to conventional chemotherapy. Rovalpituzumab tesirine', 'has been found to reduce the frequency of TICs in low passage SCLC patient-derived', 'xenograft models significantly more than platinum-based SOC therapy. By targeting this', 'resistant, residual cell population, rovalpituzumab tesirine has a unique mechanistic', 'rationale for benefit in post-chemotherapy maintenance setting. Rovalpituzumab tesirine', 'had shown promising clinical activity in subjects with recurrent/relapsed SCLC', '(Section 3.3), and it is likely that the observed benefit will translate into maintenance', 'setting. This study will assess the efficacy, tolerability, and safety of rovalpituzumab in', 'subjects with extensive-stage SCLC who have ongoing clinical benefit (SD, PR, or CR)', 'following first-line platinum-based chemotherapy (cisplatin or carboplatin in combination', 'with etoposide or irinotecan).', 'As of 30 June 2018, 1246 subjects have received study medication in the rovalpituzumab', 'tesirine clinical program; an estimated 1039 subjects (with SCLC or other DLL3- -', 'expressing solid tumors) have received at least 1 dose of rovalpituzumab tesirine at doses', 'ranging from 0.05 mg/kg to 0.8 mg/kg on a q3w schedule and 0.3 mg/kg to 0.4 mg/kg on', 'a q6w schedule.', '29']\n\n###\n\n", "completion": "END"}